Swirsky Douglas J
SEC insider (Form 3/4/5 filer). CIK 0001375884. Director at Cellectar Biosciences, Inc. (CLRB) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Jul 7, 2026. Located in FLORHAM PARK, NJ.
Companies Swirsky Douglas J has filed insider reports for
- Cellectar Biosciences, Inc. (CLRB): Director
- Barinthus Biotherapeutics plc. (BRNS): Officer, Principal Accounting Officer
- MAXCYTE, INC. (MXCT): Officer, CHIEF FINANCIAL OFFICER
Swirsky Douglas J
CIK: 0001375884
Transaction Breakdown
Open Market Buys (P)1 (16.7%)
High conviction signal
Open Market Sales (S)2 (33.3%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jul 7, 2026CLRB
Cellectar Biosciences, Inc.
AwardDirectStock option (right to buy)
37.5K shares- - Mar 17, 2026MXCT
MAXCYTE, INC.
SaleDirect10.1K shares at avg. $0.81$8K - Aug 13, 2025MXCT
MAXCYTE, INC.
PurchaseDirect50K shares at avg. $1.29$65K - Mar 18, 2025MXCT
MAXCYTE, INC.
SaleDirect6.9K shares at avg. $3.18$22K - Mar 14, 2025MXCT
MAXCYTE, INC.
AwardDirect37.5K shares- - Feb 14, 2025CLRB
Cellectar Biosciences, Inc.
AwardDirectStock option (right to buy)
90K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 7, 2026 |  CLRB Cellectar Biosciences, Inc. | Award Stock option (right to buy) | 37,500 | - | - | Direct |
| Mar 17, 2026 |  MXCT MAXCYTE, INC. | Sale | 10,142 | $0.81 | $8,266 | Direct |
| Aug 13, 2025 | MXCT MAXCYTE, INC. | Purchase | 50,000 | $1.29 | $64,500 | Direct |
| Mar 18, 2025 | MXCT MAXCYTE, INC. | Sale | 6,939 | $3.18 | $22,061 | Direct |
| Mar 14, 2025 | MXCT MAXCYTE, INC. | Award | 37,500 | - | - | Direct |
| Feb 14, 2025 | CLRB Cellectar Biosciences, Inc. | Award Stock option (right to buy) | 90,000 | - | - | Direct |
1-6 of 6 transactions